---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-051681"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:02:18.000717+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pasithea Therapeutics appoints Kartik Krishnan as Chief Medical Officer, effective May 1, 2026

## Summary
- Dr. Krishnan appointed CMO effective May 1; will lead PAS-004 clinical strategy for NF1-associated neurofibromas.
- Over 20 years of experience; previously CMO at Arcus Biosciences, contributed to cobimetinib approval for melanoma.
- Employment agreement: $500k base salary, 40% bonus eligibility, and options for 1.13M shares at $0.841 exercise price.
- CEO Tiago Reis Marques granted options for 1.76M shares; other execs/employees received 1.24M shares in aggregate.
- Non-employee directors each receive options for 152,783 shares, vesting over one year.

## SEC filing metadata
- accession: 0001213900-26-051681
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/0001213900-26-051681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/ea0288864-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-051681
- JSON: https://secwatch.observer/filing/0001213900-26-051681.json
- Plain text: https://secwatch.observer/filing/0001213900-26-051681.txt

## Key facts
- Executive change
  Kartik Krishnan was appointed as Chief Medical Officer at Pasithea Therapeutics Corp..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/0001213900-26-051681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.